Success Metrics

Completion Rate

0%(0/1)

Active Trials

1(50%)

Terminated

1(50%)

Phase Distribution

Ph early_phase_1

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution1 total trials

Early Phase 1First-in-human

1(100.0%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Terminated(1)

Detailed Status

Recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Early Phase 1

Trials by Phase

Early Phase 11 (100.0%)

Trials by Status

recruiting150%

terminated150%

Recent Activity

1 active trials

Showing 2 of 2

recruiting

Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study

NCT07079150

terminatedearly_phase_1

Pilot Study of IFN α2b for Melanoma Patients

NCT00871533

Clinical Trials (2)

Showing 2 of 2 trials

NCT07079150

Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study

Recruiting

NCT00871533Early Phase 1

Pilot Study of IFN α2b for Melanoma Patients

Terminated

All 2 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 2